Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
89 studies found for:    "Salivary Gland Neoplasms"
Show Display Options
Rank Status Study
21 Completed Imatinib Mesylate in Treating Patients With Salivary Gland Cancer
Condition: Head and Neck Cancer
Intervention: Drug: imatinib mesylate
22 Unknown  Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer
Condition: Head and Neck Cancer
Intervention: Biological: trastuzumab
23 Unknown  Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery
Condition: Head and Neck Cancer
Intervention: Drug: gemcitabine hydrochloride
24 Completed Paclitaxel in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer
Condition: Head and Neck Cancer
Intervention: Drug: paclitaxel
25 Unknown  CO(Mbined Therapy of Malignant) S(Alivary Gland tu)M(Ours With)I(MRT and) c(Arbon Ions): COSMIC
Conditions: Malignancy;   Salivary Glands;   Tumor
Intervention: Radiation: carbon ion boost
26 Completed A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands
Conditions: Recurrent Adenoid Cystic Carcinoma of the Salivary Glands;   Metastatic Adenoid Cystic Carcinoma of the Salivary Glands;   Salivary Gland Cancers;   ACC
Intervention: Drug: Dovitinib
27 Completed A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands
Conditions: Adenoid Cystic Carcinoma;   Salivary Gland Cancer
Intervention: Drug: Sunitinib
28 Completed Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck
Conditions: Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Salivary Gland Cancer;   Salivary Gland Adenoid Cystic Carcinoma;   Stage III Adenoid Cystic Carcinoma of the Oral Cavity;   Stage III Salivary Gland Cancer;   Stage IV Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IV Salivary Gland Cancer
Interventions: Drug: bortezomib;   Drug: doxorubicin hydrochloride;   Other: laboratory biomarker analysis
29 Recruiting Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands: ACC-LEN14
Condition: Adenoid Cystic Carcinomas of the Salivary Glands
Intervention: Drug: Lenvatinib
30 Not yet recruiting Investigating the Role of Mucin and Mucin Glycosylating Enzymes in Nasopharyngeal Carcinoma and Salivary Gland Cancer and Their Correlation With Clinical Prognosis
Conditions: Salivary Gland Cancer;   Nasopharyngeal Carcinoma
Intervention:
31 Active, not recruiting
Has Results
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
Conditions: Recurrent Oral Cavity Adenoid Cystic Carcinoma;   Recurrent Salivary Gland Carcinoma;   Salivary Gland Adenoid Cystic Carcinoma;   Stage IVA Major Salivary Gland Carcinoma;   Stage IVA Oral Cavity Adenoid Cystic Carcinoma;   Stage IVB Major Salivary Gland Carcinoma;   Stage IVB Oral Cavity Adenoid Cystic Carcinoma;   Stage IVC Major Salivary Gland Carcinoma;   Stage IVC Oral Cavity Adenoid Cystic Carcinoma
Interventions: Drug: Akt Inhibitor MK2206;   Other: Laboratory Biomarker Analysis
32 Active, not recruiting Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma
Conditions: Recurrent Oral Cavity Adenoid Cystic Carcinoma;   Recurrent Salivary Gland Carcinoma;   Salivary Gland Adenoid Cystic Carcinoma;   Stage III Major Salivary Gland Carcinoma;   Stage III Oral Cavity Adenoid Cystic Carcinoma;   Stage IVA Major Salivary Gland Carcinoma;   Stage IVA Oral Cavity Adenoid Cystic Carcinoma;   Stage IVB Major Salivary Gland Carcinoma;   Stage IVB Oral Cavity Adenoid Cystic Carcinoma;   Stage IVC Major Salivary Gland Carcinoma;   Stage IVC Oral Cavity Adenoid Cystic Carcinoma;   Tongue Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Vorinostat
33 Recruiting Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)
Conditions: Carcinoma, Non-Small-Cell Lung;   Thyroid Neoplasms;   Sarcoma;   Colorectal Neoplasms;   Salivary Gland Neoplasms;   Biliary Tract Neoplasms;   Brain Neoplasm, Primary;   Carcinoma, Ductal, Breast;   Melanoma;   Solid Tumors;   Glioblastoma;   Bile Duct Neoplasms;   Astrocytoma;   Head and Neck Squamous Cell Carcinoma;   Pontine Glioma
Intervention: Drug: LOXO-101
34 Terminated A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer
Conditions: Prostate Cancer;   Salivary Gland Cancer;   Endometrial Cancer;   Squamous Cell Carcinoma of the Cervix;   Breast Cancer;   Ovarian Cancer
Intervention: Drug: OPB-111001
35 Terminated Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer
Conditions: High-grade Salivary Gland Mucoepidermoid Carcinoma;   Recurrent Salivary Gland Cancer;   Salivary Gland Acinic Cell Tumor;   Salivary Gland Adenocarcinoma;   Salivary Gland Poorly Differentiated Carcinoma;   Stage IVA Salivary Gland Cancer;   Stage IVB Salivary Gland Cancer;   Stage IVC Salivary Gland Cancer
Interventions: Biological: trastuzumab;   Other: laboratory biomarker analysis
36 Terminated Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC
Conditions: Salivary Gland Squamous Cell Carcinoma;   Stage II Salivary Gland Cancer;   Stage II Squamous Cell Carcinoma of the Hypopharynx;   Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage II Squamous Cell Carcinoma of the Oropharynx;   Stage II Verrucous Carcinoma of the Oral Cavity;   Stage III Salivary Gland Cancer;   Stage III Squamous Cell Carcinoma of the Hypopharynx;   Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Verrucous Carcinoma of the Oral Cavity;   Stage IV Salivary Gland Cancer;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IV Squamous Cell Carcinoma of the Oropharynx;   Stage IV Verrucous Carcinoma of the Oral Cavity
Interventions: Radiation: intensity-modulated radiation therapy;   Drug: cisplatin;   Radiation: image-guided adaptive radiation therapy;   Other: 3'-deoxy-3'-[18F]fluorothymidine;   Procedure: positron emission tomography/computed tomography;   Radiation: fludeoxyglucose F 18
37 Active, not recruiting Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Conditions: Recurrent Hypopharyngeal Squamous Cell Carcinoma;   Recurrent Laryngeal Squamous Cell Carcinoma;   Recurrent Laryngeal Verrucous Carcinoma;   Recurrent Lip and Oral Cavity Squamous Cell Carcinoma;   Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary;   Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Recurrent Oral Cavity Verrucous Carcinoma;   Recurrent Oropharyngeal Squamous Cell Carcinoma;   Recurrent Salivary Gland Carcinoma;   Salivary Gland Squamous Cell Carcinoma;   Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary;   Stage IV Hypopharyngeal Squamous Cell Carcinoma;   Stage IV Major Salivary Gland Carcinoma;   Stage IVA Laryngeal Squamous Cell Carcinoma;   Stage IVA Laryngeal Verrucous Carcinoma;   Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVA Major Salivary Gland Carcinoma;   Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVA Oral Cavity Verrucous Carcinoma;   Stage IVA Oropharyngeal Squamous Cell Carcinoma;   Stage IVB Laryngeal Squamous Cell Carcinoma;   Stage IVB Laryngeal Verrucous Carcinoma;   Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVB Major Salivary Gland Carcinoma;   Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVB Oral Cavity Verrucous Carcinoma;   Stage IVB Oropharyngeal Squamous Cell Carcinoma;   Stage IVC Laryngeal Squamous Cell Carcinoma;   Stage IVC Laryngeal Verrucous Carcinoma;   Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVC Major Salivary Gland Carcinoma;   Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVC Oral Cavity Verrucous Carcinoma;   Stage IVC Oropharyngeal Squamous Cell Carcinoma;   Tongue Carcinoma;   Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary
Interventions: Biological: Bevacizumab;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Docetaxel;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis
38 Completed Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer
Conditions: Recurrent Hypopharyngeal Squamous Cell Carcinoma;   Recurrent Laryngeal Squamous Cell Carcinoma;   Recurrent Laryngeal Verrucous Carcinoma;   Recurrent Lip and Oral Cavity Squamous Cell Carcinoma;   Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary;   Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma;   Recurrent Oral Cavity Verrucous Carcinoma;   Recurrent Oropharyngeal Squamous Cell Carcinoma;   Recurrent Salivary Gland Carcinoma;   Salivary Gland Squamous Cell Carcinoma;   Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary;   Stage IV Hypopharyngeal Squamous Cell Carcinoma;   Stage IV Laryngeal Squamous Cell Carcinoma;   Stage IV Laryngeal Verrucous Carcinoma;   Stage IV Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IV Major Salivary Gland Carcinoma;   Stage IV Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma;   Stage IV Oral Cavity Verrucous Carcinoma;   Stage IV Oropharyngeal Squamous Cell Carcinoma;   Tongue Carcinoma;   Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary
Interventions: Drug: Cediranib Maleate;   Other: Laboratory Biomarker Analysis
39 Recruiting Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors
Conditions: Colorectal Cancer;   Bladder Carcinoma;   Squamous Cell Carcinoma of the Head and Neck;   Salivary Gland Cancer
Interventions: Biological: enadenotucirev;   Biological: nivolumab
40 Recruiting Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery
Conditions: Head and Neck Squamous Cell Carcinoma;   Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Recurrent Nasopharynx Carcinoma;   Recurrent Salivary Gland Carcinoma;   Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary;   Stage III Major Salivary Gland Carcinoma;   Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage III Nasopharyngeal Carcinoma;   Stage IV Nasopharyngeal Carcinoma;   Stage IVA Major Salivary Gland Carcinoma;   Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVB Major Salivary Gland Carcinoma;   Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVC Major Salivary Gland Carcinoma;   Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Drug: Vorinostat

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.